Status:
COMPLETED
Gut-derived Neuropeptides in Cerebrospinal Fluid of Patients With Parkinson's Disease and Healthy Controls
Lead Sponsor:
Dr. Marcus Unger
Conditions:
Parkinson's Disease
Eligibility:
All Genders
18-75 years
Brief Summary
In previous work, the investigators analyzed the concentration of gut-derived peptides (ghrelin, pancreatic polypeptide \[PP\]) in serum of patients with Parkinson's disease (PD). The investigators ha...
Eligibility Criteria
Inclusion
- Main
- Informed consent to participate
- Capability to understand risks of study-related procedures
- For PD cohort: diagnosis of (idiopathic) Parkinson's disease
- Main
Exclusion
- Pregnancy
- Subjects incompetent to provide informed consent
- Subjects that cannot undergo a lumbar puncture for medical reasons (thrombocytopenia, anticoagulation, increased cranial pressure)
- For control cohort: presence of a neurodegenerative disorder
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01792193
Start Date
January 1 2013
End Date
December 1 2015
Last Update
March 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saarland University
Homburg / Saar, Saarland, Germany, 66421